**Table S6. Canonical pathways for all analyses**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Exposure status** | **Survival/Immune status** | **CNS location** |
| **Canonical Pathways** |  **-log****(p-value)** | **Transcripts**  |  **-log****(p-value)**  | **Transcripts**  |  **-log****(p-value)**  | **Transcripts**  |
|  α-Adrenergic Signaling | 1.89E+00 | 11 | 2.21E+00 | 11 | 4.35E+00 | 14 |
|  Amyotrophic Lateral Sclerosis Signaling\* | 1.75E+00 | 12 | 1.64E+00 | 14 | 4.75E+00 | 15 |
|  Antiproliferative Role of Somatostatin Receptor 2 |  |  |  |  | 3.49E+00 | 11 |
|  Axonal Guidance Signaling\* |  |  | 1.84E+00 | 29 |  |  |
|  β-alanine Metabolism | 1.93E+00 | 8 |  |  |  |  |
|  Breast Cancer Regulation by Stathmin1 |  |  |  |  | 4.95E+00 | 23 |
|  Butanoate Metabolism | 1.55E+00 | 8 |  |  |  |  |
|  Calcium Signaling |  |  | 2.68E+00 | 21 |  |  |
|  Calcium Signaling |  |  |  |  | 3.45E+00 | 19 |
|  cAMP-mediated Signaling | 1.71E+00 | 18 | 2.75E+00 | 18 | 4.04E+00 | 19 |
|  Cardiac β-adrenergic Signaling | 1.99E+00 | 16 | 2.52E+00 | 16 | 5.05E+00 | 18 |
|  Caveolar-mediated Endocytosis Signaling |  |  | 1.75E+00 | 8 |  |  |
|  CDK5 Signaling\* | 1.89E+00 | 11 | 1.76E+00 | 9 |  |  |
|  Corticotropin Releasing Hormone Signaling | 1.55E+00 | 13 | 2.36E+00 | 13 |  |  |
| CREB Signaling in Neurons\* | 2.41E+00 | 19 | 2.84E+00 | 21 | 6.23E+00 | 24 |
|  CXCR4 Signaling^ |  |  |  |  | 3.71E+00 | 18 |
|  Dopamine Receptor Signaling\* | 2.41E+00 | 11 | 1.72E+00 | 8 |  |  |
|  EGF Signaling |  |  |  |  | 3.92E+00 | 9 |
|  Endothelin-1 Signaling | 2.07E+00 | 19 |  |  | 4.08E+00 | 20 |
|  G Beta Gamma Signaling | 1.78E+00 | 11 | 2.11E+00 | 11 | 4.18E+00 | 14 |
|  Glutamate Receptor Signaling\* | 1.70E+00 | 9 | 5.02E+00 | 15 | 5.77E+00 | 13 |
|  GNRH Signaling | 1.90E+00 | 15 |  |  |  |  |
|  G-Protein Coupled Receptor Signaling |  |  | 3.40E+00 | 24 | 7.28E+00 | 29 |
|  IL-10 Signaling^ | 1.62E+00 | 8 |  |  |  |  |
|  Leptin Signaling in Obesity |  |  | 2.77E+00 | 11 |  |  |